What will lead the next revolution in cancer care in the next decade?

In the past few decades, the advent of a series of innovative treatments has brought the level of cancer treatment to an unprecedented level, but we have to admit the fact that human efforts to conquer cancer are far from enough

Humanity's efforts to conquer cancer are far from enough

Received the honor of " Oncology Giant" Chief Patient Officer of the American Cancer Society Singapore Clinical Research and Innovation Alliance under the Singapore Ministry of Health .

▲ Breaking through the difficulties of cancer diagnosis and treatment ( April 27, Beijing time, 11:00-14:00 )

▲ Breaking through the difficulties of cancer diagnosis and treatment ▲ ( April 27, Beijing time, 11:00-14:00 )

On the first day of the forum, Professor Mo Shujin from the Chinese University of Hong Kong will talk to the Chief Patient Officer of the American Cancer Society and the clinical oncologist of the Dana-Farber Cancer Institute : Early clinical trials are time-consuming and difficult to recruit patients.

Prof.

▲ Foresight perspective: next-generation technology to overcome cancer treatment ( April 28, Beijing time, 11:00-14:00 )

▲ Foresight perspective: next-generation technology to overcome cancer treatment ( Beijing time, April 28, 11:00-14:00 11:00-14:00 )

On the second day's agenda, guests from Walking Fish, Scorpion, Kojin, several cutting-edge companies focusing on the research and development of cutting-edge anti-tumor drugs, as well as investors from Apple Tree Partners and Droia Ventures, venture capital institutions in the field of oncology, will share their thoughts.

At present, protein degradation technologies such as PROTAC and molecular glue, which are expected to overcome "non-drugable" targets, ferroptosis therapy targeting new apoptosis pathways, and next-generation technologies that innovatively utilize B cells have laid a solid foundation for a revolution in cancer treatment.

Faced with opportunities and challenges, how should investors and biotech companies cooperate to usher in a major breakthrough? In this discussion, we will hear valuable experience from the front line of R&D

▲ Focus on Singapore: The Transformation Center of Cell and Gene Therapy in Asia-Pacific Oncology ( April 29, Beijing time, 11:00-14:00 )

▲ Focus on Singapore: A Transformational Center for Cell and Gene Therapy in Asia-Pacific Oncology ▲ ( April 29, Beijing time, 11:00-14:00 11:00-14:00 )

In the third day of the agenda, we will use cell and gene therapy as an example to do a more in-depth discussion

Singapore's Alliance for Clinical Research and Innovation under the Ministry of Health, Singapore Health Sciences Authority of Singapore, Singapore Agency for Science, Technology and Research

As one of the innovation centers in the Asia-Pacific region, Singapore has created a unique R&D model - under the close integration of academic circles and industrial circles, there are many start-up companies at different nodes in the entire industrial chain.

Dr.

References:

[1] World Health Organization website.

[2] AACR Cancer Progress Report 2021.

[3] The road is coming, witnessing the industrialization of cell and gene therapy.

[4] Regenerative Medicine: Disrupting the Status Quo.